Compare
Replimune Group, Inc. vs Prokidney Corp. vs Prime Medicine, Inc. vs Taysha Gene Therapies, Inc.
| Latest fiscal year | Replimune Group, Inc. REPL | Prokidney Corp. PROK | Prime Medicine, Inc. PRME | Taysha Gene Therapies, Inc. TSHA |
|---|---|---|---|---|
| Year ended | 2026-03-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $893.0K | $4.63M | $9.77M |
| Revenue growth (YoY) | n/a | n/m | +55.3% | +17.3% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/m | n/m |
| Net margin | n/a | n/m | n/m | n/m |
| Net income | -$313.94M | -$151.61M | -$201.14M | -$109.00M |
| EPS (Diluted) | -$3.38 | n/a | -$1.35 | -$0.34 |
| Operating cash flow | -$280.34M | -$120.12M | -$162.56M | -$93.09M |
| Free cash flow | -$284.57M | -$135.31M | -$167.09M | -$93.83M |
| Cash & equivalents | $209.02M | $108.54M | $63.03M | $319.77M |
| Total assets | $332.39M | $335.57M | $342.73M | $343.32M |
| Total liabilities | $166.23M | $34.78M | $221.87M | $96.38M |
| Shareholders' equity | $166.16M | -$1.01B | $120.87M | $246.94M |
| Return on year-end equity | -188.9% | n/a | -166.4% | -44.1% |
| Shares outstanding | 82.72M | n/a | 180.51M | 285.05M |
Revenue, most recent five fiscal years
| Fiscal year | Replimune Group, Inc. | Prokidney Corp. | Prime Medicine, Inc. | Taysha Gene Therapies, Inc. |
|---|---|---|---|---|
| Latest | n/a | $893.0K Ended 2025-12-31 | $4.63M Ended 2025-12-31 | $9.77M Ended 2025-12-31 |
| 1 year earlier | n/a | $76.0K Ended 2024-12-31 | $2.98M Ended 2024-12-31 | $8.33M Ended 2024-12-31 |
| 2 years earlier | n/a | $0 Ended 2023-12-31 | $0 Ended 2023-12-31 | $15.45M Ended 2023-12-31 |
| 3 years earlier | n/a | $0 Ended 2022-12-31 | $0 Ended 2022-12-31 | $2.50M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $0 Ended 2021-12-31 | n/a |